Scotia Capital’s Outlook Therapeutics OTLK Stock Holding History

Scotia Capital’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.6K	Buy	+46,300	New	+$28.7K	﹤0.01%	893
2026 Q1	–	Sell	-73,989	Closed	-$117K	–	965
2025 Q4	$117K	Hold	73,989	–	–	﹤0.01%	866
2025 Q3	$78.4K	Hold	73,989	–	–	﹤0.01%	887
2025 Q2	$118K	Sell	73,989 -50	-0.1%	-$80	﹤0.01%	822
2025 Q1	$90.3K	Buy	74,039 +50	+0.1%	+$88	﹤0.01%	814
2024 Q4	$140K	Buy	73,989 +41,023	+124%	+$169K	﹤0.01%	809
2024 Q3	$176K	Hold	32,966	–	–	﹤0.01%	783
2024 Q2	$243K	Buy	32,966 +9,271	+39%	+$74.4K	﹤0.01%	722
2024 Q1	$283K	Buy	23,695 +9,491	+67%	+$76.7K	﹤0.01%	700
2023 Q4	$112K	Sell	14,204 -2,718	-16%	-$23K	﹤0.01%	762
2023 Q3	$74.8K	Buy	16,922 +13,673	+421%	+$303K	﹤0.01%	743
2023 Q2	$113K	Buy	+3,249	New	+$88.6K	﹤0.01%	746

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

Scotia Capital's OTLK Position: Q2 2026 in Review

Scotia Capital opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 46,300 shares worth $73.6K. The stake represents ﹤0.01% of the portfolio and ranks #893 among its holdings. This is a return to the name: Scotia Capital previously reported a position in OTLK as recently as Q4 2025.

Scotia Capital first reported a position in OTLK in Q2 2023 and has held it in 12 quarters since. The position peaked at $283K in Q1 2024. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Scotia Capital held 46,300 shares of Outlook Therapeutics worth $73.6K as of Q2 2026.
Outlook Therapeutics was a new Scotia Capital position in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of Scotia Capital's portfolio in Q2 2026, its #893 holding.
Scotia Capital first reported a position in Outlook Therapeutics in Q2 2023 and has held it in 12 quarters since.
Scotia Capital's Outlook Therapeutics position peaked at $283K in Q1 2024.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.